Cytophage Technologies Ltd.
Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and … Read more
Cytophage Technologies Ltd. (CYTO) - Net Assets
Latest net assets as of : CA$- CAD
Based on the latest financial reports, Cytophage Technologies Ltd. (CYTO) has net assets worth CA$- CAD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$-) and total liabilities (CA$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cytophage Technologies Ltd. - Net Assets Trend (None–None)
This chart illustrates how Cytophage Technologies Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cytophage Technologies Ltd. (None–None)
The table below shows the annual net assets of Cytophage Technologies Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Cytophage Technologies Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Cytophage Technologies Ltd. Competitors by Market Cap
The table below lists competitors of Cytophage Technologies Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rothwell International Co. Limited
KQ:900260
|
$2.88 Million |
|
YPSOMED HLDG N
MU:OWX
|
$2.88 Million |
|
Oncozenge AB
ST:ONCOZ
|
$2.88 Million |
|
Spacetalk Ltd
AU:SPA
|
$2.88 Million |
|
NOST.TERRA OIL+G. LS-001
F:LMU1
|
$2.88 Million |
|
Raj Rayon Industries Limited
NSE:RAJRILTD
|
$2.87 Million |
|
Lodestar Minerals Ltd
AU:LSR
|
$2.87 Million |
|
Pardee Resources Co
PINK:PDER
|
$2.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cytophage Technologies Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Cytophage Technologies Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Cytophage Technologies Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Cytophage Technologies Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,651,653
- Average return on equity (ROE) among peers: 43.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cytophage Technologies Ltd. (CYTO) | CA$- | N/A | N/A | $2.88 Million |
| Innovotech Inc (IOT) | $181.51K | 415.07% | 1.90x | $4.32 Million |
| Rakovina Therapeutics Inc (RKV) | $4.30 Million | -94.74% | 0.45x | $1.14 Million |
| Thiogenesis Therapeutics Corp. (TTI) | $83.35K | -111.19% | 0.76x | $14.25 Million |
| Waverley Pharma Inc (WAVE) | $2.04 Million | -34.55% | 0.71x | $235.88K |